Tissue | Expression Dynamics | Abbreviation |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/AKT3_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/AKT3_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/AKT3_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/AKT3_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003253520 | Esophagus | ESCC | regulation of cellular component size | 227/8552 | 383/18723 | 4.77e-08 | 8.60e-07 | 227 |
GO:000756820 | Esophagus | ESCC | aging | 201/8552 | 339/18723 | 2.64e-07 | 3.94e-06 | 201 |
GO:0048872111 | Esophagus | ESCC | homeostasis of number of cells | 163/8552 | 272/18723 | 1.40e-06 | 1.69e-05 | 163 |
GO:00182099 | Esophagus | ESCC | peptidyl-serine modification | 196/8552 | 338/18723 | 3.07e-06 | 3.47e-05 | 196 |
GO:001810515 | Esophagus | ESCC | peptidyl-serine phosphorylation | 184/8552 | 315/18723 | 3.22e-06 | 3.61e-05 | 184 |
GO:00319294 | Esophagus | ESCC | TOR signaling | 79/8552 | 126/18723 | 8.57e-05 | 6.21e-04 | 79 |
GO:005067318 | Esophagus | ESCC | epithelial cell proliferation | 238/8552 | 437/18723 | 1.19e-04 | 8.20e-04 | 238 |
GO:00083619 | Esophagus | ESCC | regulation of cell size | 107/8552 | 181/18723 | 1.81e-04 | 1.16e-03 | 107 |
GO:00075699 | Esophagus | ESCC | cell aging | 81/8552 | 132/18723 | 2.00e-04 | 1.27e-03 | 81 |
GO:005067817 | Esophagus | ESCC | regulation of epithelial cell proliferation | 206/8552 | 381/18723 | 5.51e-04 | 3.02e-03 | 206 |
GO:00000021 | Esophagus | ESCC | mitochondrial genome maintenance | 17/8552 | 21/18723 | 1.03e-03 | 5.19e-03 | 17 |
GO:000166720 | Esophagus | ESCC | ameboidal-type cell migration | 250/8552 | 475/18723 | 1.22e-03 | 5.97e-03 | 250 |
GO:00320061 | Esophagus | ESCC | regulation of TOR signaling | 63/8552 | 104/18723 | 1.55e-03 | 7.29e-03 | 63 |
GO:00320082 | Esophagus | ESCC | positive regulation of TOR signaling | 31/8552 | 47/18723 | 4.01e-03 | 1.62e-02 | 31 |
GO:001063120 | Esophagus | ESCC | epithelial cell migration | 187/8552 | 357/18723 | 6.05e-03 | 2.23e-02 | 187 |
GO:009013220 | Esophagus | ESCC | epithelium migration | 188/8552 | 360/18723 | 6.96e-03 | 2.54e-02 | 188 |
GO:009013020 | Esophagus | ESCC | tissue migration | 190/8552 | 365/18723 | 7.91e-03 | 2.82e-02 | 190 |
GO:00903984 | Esophagus | ESCC | cellular senescence | 54/8552 | 93/18723 | 1.08e-02 | 3.67e-02 | 54 |
GO:000756818 | Oral cavity | OSCC | aging | 194/7305 | 339/18723 | 6.18e-12 | 2.33e-10 | 194 |
GO:004887220 | Oral cavity | OSCC | homeostasis of number of cells | 152/7305 | 272/18723 | 1.08e-08 | 2.23e-07 | 152 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
AKT3 | SNV | Missense_Mutation | novel | c.1154N>A | p.Pro385Gln | p.P385Q | Q9Y243 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-AP-A1DV-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AKT3 | SNV | Missense_Mutation | | c.1100N>A | p.Arg367Gln | p.R367Q | Q9Y243 | protein_coding | tolerated(0.16) | benign(0.03) | TCGA-AX-A05Z-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | SD |
AKT3 | SNV | Missense_Mutation | novel | c.1056N>T | p.Glu352Asp | p.E352D | Q9Y243 | protein_coding | tolerated(0.32) | benign(0.046) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
AKT3 | SNV | Missense_Mutation | novel | c.1180N>A | p.Asp394Asn | p.D394N | Q9Y243 | protein_coding | tolerated(0.33) | benign(0.007) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AKT3 | SNV | Missense_Mutation | | c.899N>T | p.Ala300Val | p.A300V | Q9Y243 | protein_coding | deleterious(0) | benign(0.062) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AKT3 | SNV | Missense_Mutation | | c.325N>A | p.Leu109Met | p.L109M | Q9Y243 | protein_coding | deleterious(0.04) | possibly_damaging(0.903) | TCGA-AX-A0J1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
AKT3 | SNV | Missense_Mutation | novel | c.571G>A | p.Ala191Thr | p.A191T | Q9Y243 | protein_coding | tolerated(0.12) | benign(0.311) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
AKT3 | SNV | Missense_Mutation | novel | c.850C>A | p.His284Asn | p.H284N | Q9Y243 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-AX-A3FT-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AKT3 | SNV | Missense_Mutation | | c.1256T>C | p.Val419Ala | p.V419A | Q9Y243 | protein_coding | tolerated(0.67) | benign(0) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
AKT3 | SNV | Missense_Mutation | | c.834G>A | p.Met278Ile | p.M278I | Q9Y243 | protein_coding | deleterious(0.03) | benign(0.375) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 249565578 | IPATASERTIB | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | inhibitor | GSK2126458 | OMIPALISIB | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | inhibitor | 249565585 | UPROSERTIB | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | | Afuresertib | AFURESERTIB | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | | MK2206 | MK-2206 | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | | BAY1125976 | | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | | GSK2141795 | UPROSERTIB | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | allosteric modulator | 328083529 | MIRANSERTIB | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | inhibitor | CHEMBL494089 | GSK-690693 | |
10000 | AKT3 | DRUGGABLE GENOME, KINASE, ENZYME, DRUG RESISTANCE, SERINE THREONINE KINASE, CLINICALLY ACTIONABLE | | PERIFOSINE | PERIFOSINE | |